Amgen (AMGN) – Investment Analysts’ Recent Ratings Changes

Amgen (NASDAQ: AMGN) recently received a number of ratings updates from brokerages and research firms:

  • 11/19/2026 – Amgen had its “overweight” rating reaffirmed by Piper Sandler. They now have a $542.00 price target on the stock, up from $457.00.
  • 11/16/2026 – Amgen had its price target raised by Barclays from $400.00 to $430.00. They now have an “equal weight” rating on the stock.
  • 11/12/2026 – Amgen had its price target raised by Argus from $460.00 to $515.00. They now have a “buy” rating on the stock.
  • 11/6/2026 – Amgen was downgraded by Freedom Broker from “buy” to “hold”. They now have a $470.00 price target on the stock, up from $450.00.
  • 11/5/2026 – Amgen had its price target raised by Leerink Partners from $395.00 to $464.00. They now have a “market perform” rating on the stock.
  • 11/5/2026 – Amgen had its price target raised by Guggenheim from $378.00 to $435.00. They now have a “neutral” rating on the stock.
  • 11/4/2026 – Amgen had its price target raised by TD Cowen from $452.00 to $531.00. They now have a “buy” rating on the stock.
  • 11/4/2026 – Amgen had its price target raised by Sanford C. Bernstein from $345.00 to $400.00. They now have a “market perform” rating on the stock.
  • 11/4/2026 – Amgen had its price target raised by Royal Bank Of Canada from $430.00 to $470.00. They now have an “outperform” rating on the stock.
  • 11/4/2026 – Amgen had its price target raised by Canaccord Genuity Group from $384.00 to $440.00. They now have a “hold” rating on the stock.
  • 11/4/2026 – Amgen had its price target raised by Wells Fargo & Company from $430.00 to $460.00. They now have an “equal weight” rating on the stock.
  • 11/4/2026 – Amgen had its “outperform” rating reaffirmed by William Blair.
  • 11/4/2026 – Amgen had its price target raised by UBS Group from $470.00 to $530.00. They now have a “buy” rating on the stock.
  • 11/4/2026 – Amgen had its price target raised by Scotiabank from $500.00 to $530.00. They now have a “sector outperform” rating on the stock.
  • 11/4/2026 – Amgen had its price target raised by Citigroup from $405.00 to $465.00. They now have a “neutral” rating on the stock.
  • 11/4/2026 – Amgen had its price target raised by JPMorgan Chase & Co. from $350.00 to $425.00. They now have a “neutral” rating on the stock.
  • 11/4/2026 – Amgen had its price target raised by The Goldman Sachs Group from $481.00 to $536.00. They now have a “buy” rating on the stock.
  • 11/4/2026 – Amgen had its price target raised by Morgan Stanley from $359.00 to $410.00. They now have an “equal weight” rating on the stock.
  • 11/4/2026 – Amgen had its price target raised by Truist Financial from $380.00 to $398.00. They now have a “hold” rating on the stock.
  • 11/4/2026 – Amgen had its price target raised by Cantor Fitzgerald from $440.00 to $465.00. They now have a “neutral” rating on the stock.
  • 10/23/2026 – Amgen had its “outperform” rating reaffirmed by Oppenheimer.
  • 10/23/2026 – Amgen had its price target raised by Oppenheimer from $450.00 to $480.00. They now have an “outperform” rating on the stock.
  • 10/21/2026 – Amgen had its price target raised by Barclays from $380.00 to $400.00. They now have an “equal weight” rating on the stock.
  • 10/18/2026 – Amgen was upgraded by Wall Street Zen from “hold” to “buy”.
  • 10/13/2026 – Amgen had its price target lowered by Guggenheim from $388.00 to $378.00. They now have a “neutral” rating on the stock.
  • 10/12/2026 – Amgen had its price target lowered by BMO Capital Markets from $450.00 to $415.00. They now have a “market perform” rating on the stock.
  • 10/12/2026 – Amgen had its price target lowered by Wells Fargo & Company from $435.00 to $430.00. They now have an “equal weight” rating on the stock.
  • 10/10/2026 – Amgen was downgraded by Wall Street Zen from “buy” to “hold”.
  • 10/9/2026 – Amgen had its price target raised by UBS Group from $430.00 to $470.00. They now have a “buy” rating on the stock.
  • 10/8/2026 – Amgen was upgraded by Weiss Ratings from “buy (b)” to “buy (b+)”.
  • 10/8/2026 – Amgen had its price target raised by Royal Bank Of Canada from $400.00 to $430.00. They now have an “outperform” rating on the stock.
  • 10/7/2026 – Amgen had its price target raised by Truist Financial from $362.00 to $380.00. They now have a “hold” rating on the stock.
  • 10/7/2026 – Amgen had its price target lowered by Morgan Stanley from $362.00 to $359.00. They now have an “equal weight” rating on the stock.
  • 10/5/2026 – Amgen had its price target raised by Cantor Fitzgerald from $400.00 to $440.00. They now have a “neutral” rating on the stock.
  • 9/28/2026 – Amgen had its price target raised by Scotiabank from $450.00 to $500.00. They now have an “outperform” rating on the stock.
  • 9/23/2026 – Amgen had its “hold” rating reaffirmed by Jefferies Financial Group. They now have a $410.00 price target on the stock.
  • 9/23/2026 – Amgen had its “outperform” rating reaffirmed by Oppenheimer.

Amgen Stock Performance

Shares of AMGN traded down $3.55 during trading hours on Thursday, reaching $440.34. 1,207,308 shares of the company traded hands, compared to its average volume of 2,737,675. Amgen Inc. has a 1-year low of $312.39 and a 1-year high of $483.99. The company has a debt-to-equity ratio of 3.60, a quick ratio of 1.20 and a current ratio of 1.48. The stock has a market cap of $238.18 billion, a P/E ratio of 25.54, a price-to-earnings-growth ratio of 3.19 and a beta of 0.43. The stock’s fifty day moving average is $428.15 and its 200 day moving average is $382.85.

Amgen (NASDAQ:AMGN – Get Free Report) last released its quarterly earnings data on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. The company had revenue of $10.37 billion for the quarter, compared to the consensus estimate of $10.07 billion. Amgen had a return on equity of 114.99% and a net margin of 24.14%. The company’s quarterly revenue was up 8.5% on a year-over-year basis. During the same period in the previous year, the business earned $5.64 earnings per share. Equities research analysts anticipate that Amgen Inc. will post 23.37 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be paid a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Friday, November 20th. Amgen’s dividend payout ratio is 58.47%.

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.

Further Reading

Receive News & Ratings for Amgen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc and related companies with MarketBeat.com's FREE daily email newsletter.